The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Nov 7, 2019. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q3 FY2019, filed Nov 7, 2019
The sections below describe the company as of the FY2018 annual report.
Developed oral drug candidates that targeted part of the immune system for people with rare kidney and blood diseases.
10-K for FY2018, filed Mar 7, 2019
It earned money from Janssen under a drug-development partnership through research payments and a payment when a clinical milestone was reached; it had not earned money from drug sales.
10-K for FY2018, filed Mar 7, 2019Prior to the adoption of ASU No. 2014-09, the Company recognized revenue from contract research and development and research progress…View ↗
Under the terms of the Janssen Agreement, the Company earned a $15,000 clinical milestone payment in December 2016 and would have been…View ↗
To date, we have not generated any revenue from the commercial sale of any drugs. During the years ended December 31, 2018 and 2017 we did…View ↗
$15M
10-K for FY2018, filed Mar 7, 2019
$15M ↗
Janssen had held exclusive worldwide rights to develop and commercialize the company's hepatitis C candidates under a collaboration. For future approved drugs, the company had planned to use its own specialized sales team in North America or license rights to third parties in some markets.
10-K for FY2018, filed Mar 7, 2019Prior to the adoption of ASU No. 2014-09, the Company recognized revenue from contract research and development and research progress…View ↗
We intend to establish our own sales and marketing capabilities if and when we obtain regulatory approval of our product candidates. In…View ↗
Outside of North America, and in situations or markets where a more favorable return may be realized through licensing commercial rights to…View ↗
No. It lost $61.7M in FY2016.
10-K for FY2018, filed Mar 7, 2019
10-Q for Q3 FY2019, filed Nov 7, 2019
−$19.6MView ↗
8-K, filed Jan 28, 2020
Effective as of the effective time of the Merger (the “Effective Time”), each share of Company common stock (a “Share”) issued and…View ↗
Grew. Revenue grew 5.8x in 4 years, from $2.6M in FY2012 to $15M in FY2016, about 55% a year.
Moved away from HCV
The earlier report covered infectious-disease drug discovery and an HCV collaboration alongside complement medicines. The later report focused on complement inhibitors and said it had no plans to advance the HCV program.
10-K for FY2015, filed Feb 25, 2016 10-K for FY2018, filed Mar 7, 2019
Expanded kidney-disease focus
The earlier report emphasized PNH and other blood, muscle and eye conditions as possible uses; the later report focused on rare kidney diseases alongside PNH.
10-K for FY2015, filed Feb 25, 2016 10-K for FY2018, filed Mar 7, 2019The complement system is a part of the human innate immune system and is believed to be comprised of three pathways: the alternative…View ↗
Competes with Alexion, Akari Therapeutics, Amgen, Amyndas Pharmaceuticals, Apellis Pharmaceuticals, BioCryst Pharmaceuticals, ChemoCentryx, Ionis Pharmaceuticals, Novartis, Omeros, Ra Pharmaceuticals, Regeneron Pharmaceuticals, and F. Hoffmann-La Roche
10-K for FY2018, filed Mar 7, 2019The development and commercialization of new drug products is highly competitive. We expect that we and our future collaborators, if any…View ↗
Loading...
